Pulmonary vein thromboses;ncRNA;64-MDCT;Dabigatran;SLC5A7
Pulmonary vein thromboses (PVTs) are believed to be rare; however, using 64-slice multidetector CT (64-MDCT), I have reported a number of cases of PVT in elderly patients with chest pains since 2012 ; ; ; ; ; ; ; ;  ; . In 2014, I reported that 61% (35 patients) of 57 elderly patients with chest pain had PVTs , which suggests that PVTs are common in elderly patients with chest pain. PVTs can release microclots that can occlude the microarteries of all organs, which inhibits the supply of oxygen and nutrients by inhibiting the arterial flow. Such conditions can cause and promote heart failure and activate nuclear respiratory factor-1 (NRF-1; CGCRTGCGCR), metal responsive transcription factor-1 (MTF-1; TGCRCNC) and hypoxia inducible factors (HIFs; RCGTG). These transcription factors and c-Myc (CACGTG) might bind and co-function on CGCGTGCGCACGTG sequences, which are termed NMHs. SLC5A7 (a choline transporter) is known to be associated with heart rate variability. SLC5A7 has an NMH that is 481 Kb from the ATG start codon that contains the sequence TGTGTGTGTGTGTGT GTGTGCGCGCACACG (termed FRONT1) before the NMH. A 29-nt FRONT1 is included in the ncRNA (LOC 101927056), and a 30-nt FRONT1 is included in the near regions of genes such as FZD7 (cardiac differentiation), SERPINE2, FAM124B, OR2A2, LAMP3, CSMD1, SOX-11 and GRM1. Additionally, FRONT1 is highly conserved in Sjogren syndrome antigen B (SSB), which is associated with cardiovascular disease, PDIA6, PPARA (acute myocardial infarction), PDE3A (cardiac remodeling), CRIM1 (chronic heart failure), AFF2, SOX2-OT and PAX4 (transcriptional modulator) (Fig. 1). Some of these genes are associated with cardiovascular disease.
Schematic overview of possible function of ncRNA (101927056) in the regulation of several gene expression levels.
Initially, FRONT1 + NMH might be activated, and ncRNA might subsequently be activated by FRONT1. The FRONT1 of LOC 101927056 has no NMH at all. Finally, ncRNA might activate many other genes, and these genes might form a network that changes the characteristics of to survive under new hypoxic and undernourished conditions. Cardiovascular agents cannot reach the pathologic parts of the heart through occluded microvessels. I have reported some PVT cases in which warfarin  and dabigatran ; ;  ;  dissolved the PVTs. Warfarin and dabigatran might ameliorate cardiovascular disease by increasing microarterial blood flow. FRONT1 might be useful as a novel prognostic factor and a new target for the development of drugs for cardiovascular disease. Microclots released from PVTs might occlude small coronary arteries and cause slow flow syndrome of the coronary arteries. To clarify these relationships, additional studies are needed. It is important to use 64-MDCT to demonstrate PVTs when we estimate the effects of anticoagulants on PVTs.
The author reports no relationships that could be construed as a conflict of interest.